Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer

Introduction: Advanced non-small cell lung cancer (aNSCLC) is an incurable disease. The effort to develop treatments with more effective systemic agents continues. This has led to the FDA approval of one antibody–drug conjugate (ADC) and eight immune checkpoint inhibitors (ICIs) for patients with aN...

Full description

Bibliographic Details
Main Authors: Idoko Salifu, Navneet Singh, Maria Berraondo, Jordi Remon, Stephanie Salifu, Eric Severson, Angela Quintana, Sandra Peiró, Shakti Ramkissoon, Laura Vidal, Isagani Chico, Kamal S. Saini
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Cancer Treatment and Research Communications
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294223000345

Internet

http://www.sciencedirect.com/science/article/pii/S2468294223000345

Similar Items